gamma-aminobutyric acid type A receptor subunit deltaGenealiases: EIG10 · EJM7 · GABAARdelta · GEFSP5
Q-omics provides the consensus-scored GABRD profile across patient tissues and cancer cell-line models. GABRD expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GABRD is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, GABRD RNA expression shows 16,710 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where GABRD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRD survival associations across molecular data types. GABRD RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRD RNA expression–survival associations across cancer types. High GABRD expression shows unfavorable associations in KIRP, COAD, ACC and UVM, but favorable associations in KIRC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GABRD RNA expression.
This table summarizes GABRD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GABRD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRD shows higher tumor expression in KIRC, HNSC, COAD, LIHC, STAD and LUAD. The KIRC box plot shows higher GABRD RNA expression in tumor versus normal tissue (log2 FC = +4.418, t-test p < 0.001).
This table shows molecular features associated with GABRD in patient tissues and cancer cell lines. In patient samples, GABRD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
